VYNE Therapeutics Inc. · NASDAQ:VYNE

VYNE Therapeutics — Investor Presentation (January 2023)

54 slides from VYNE Therapeutics's investor presentation, January 2023

  1. Slide 1: Investor Presentation January 2023

    INVESTOR PRESENTATION January 2023

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 199 including, but not limited to, statements regarding clinical development and timelines for VYNE’s BET inhibitor platform, VYNE’s development stra

  3. Slide 3: Investment Highlights

    Investment Highlights (NASDAQ: VYNE) VYNE is focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions Proven Development Potential for Innovative InhiBET™ Capabilities and Leading Multiple Near-term Pipeline Platform Advisory Inf

  4. Slide 4: Building a Leading Early-Stage Pipeline to Address Unmet Needs in I&I Conditions

    Building a Leading Early-Stage Pipeline to Address Unmet Needs in I&I Conditions Multiple paths to potential value creation and catalysts through 2024 Compound Target Indication / Therapeutic Area Stage of Development VYN201 • IND submitted “Soft” pan-BD BET inhibitor Vitiligo • November 2022: Phase

  5. Slide 5: InhiBET BET Inhibitor Platform

    InhiBET™ BET Inhibitor Platform Bromodomain & Extra-Terminal Domain (BET) Inhibition for Immunology and Inflammatory Diseases 5

  6. Slide 6: BET Proteins Play a Key Role

    BET Proteins Play a Key Role in the Regulation of Inflammatory and Oncogenic Genes involved in Several Diseases BRD4 BET proteins “read” acetylated lysines and enable transcription of: N-terminal of histones Pro-inflammatory genes, leading to: • Increased cytokine expression that activate B&T cells

  7. Slide 7: How BET Proteins Fuel the Vicious Cycle

    How BET Proteins Fuel the “Vicious Cycle” of Pro-Inflammatory Cytokine Production in Autoimmune Diseases Pro-inflammatory cytokines Cytokines bind to 1 cytokine receptors Activation of 2 cytokine NF-κβ kinase complex translation 6 Nuclear 3 translocation BRD4 4 Recruitment of cytokine transcription

  8. Slide 8: BET Inhibitors Block BD1/BD2 Binding

    BET Inhibitors Block BD1/BD2 Binding to Acetylated Lysines and Stall Pro-inflammatory Protein Transcription Pro-inflammatory cytokines cytokines 5 1 BET INHIBITOR Binds BD1 and/or BD2 of BRD4 protein making it 4 unable recognize acetylated cytokine histones, recruit translation transcription factors

  9. Slide 9: InhiBET BET Inhibitor Platform Overview

    InhiBET™ BET Inhibitor Platform Overview Platform includes global rights to a library of NCEs for any indication VYN201 VYN202 Locally administered Pan-BD BET inhibitor Oral BD2-selective BET inhibitor Designed to address diseases involving Designed to selectively bind to BD2 and is multiple, divers

  10. Slide 10: VYN201

    VYN201 Locally administered pan-BET inhibitor

  11. Slide 11: VYN201 Pre-Clinical Efficacy Model Evaluations

    VYN201 Pre-Clinical Efficacy Model Evaluations Program designed to investigate the targeted administration of a “soft drug” pan-BD BET inhibitor to maximize local effect and minimize systemic exposure Indication/area Model Administration Route Status Th17 autoimmune diseases IMI-induction mouse mode

  12. Slide 12: Preclinical Proof-of-Concept Data Summary

    VYN201: Preclinical Proof-of-Concept Data Summary Potential “pipeline in a product” with broad utility across multiple routes of administration Preclinical models produced consistent reductions in pro-inflammatory & disease-related biomarkers, improvements in disease severity and a demonstrated loca

  13. Slide 13: Vitiligo Disease / Market Overview

    VYN201: Vitiligo Disease / Market Overview

  14. Slide 14: Vitiligo – Disease Overview

    Vitiligo – Disease Overview An acquired disorder of dermatologic pigmentation with high impact on self-esteem • Vitiligo is a depigmenting skin disorder Pathophysiology & Clinical Presentation characterized by the loss of melanocytes, which causes typical non-scaly, chalky-white macules • Pathogenes

  15. Slide 15: Vitiligo – Treatment Paradigm

    Vitiligo – Treatment Paradigm Only one drug currently approved; Treatment is dominated by non-specific therapeutics Current Treatment Paradigm 1L Corticosteroids Treatment modality is dependent on disease area Vitiligo Key Unmet Need Phototherapy (segmental vs. non-segmental) as well as activity Top

  16. Slide 16: Vitiligo – Epidemiology and Pricing

    Vitiligo – Epidemiology and Pricing Large market with high unmet need and lack of approved prescription treatment options U.S. Addressable Patients U.S. Pricing Potential / Analogs Literature suggests • A topical product as an alternative to steroids and/or calcineurin 4 ~60% of patients inhibitors

  17. Slide 17: Vitiligo Preclinical data and Clinical Plan

    VYN201: Vitiligo Preclinical data and Clinical Plan

  18. Slide 18: Human Tissue Model of Vitiligo – Demonstrated Inhibition of MMP9

    VYN201: Human Tissue Model of Vitiligo – Demonstrated Inhibition of MMP9 Reconstituted human epithelial (RHE) skin cultures were treated with a TNF-α and IFN-ɣ cytokine cocktail to induce a vitiligo phenotype melanocytorrhagy (loss of melanocyte), upregulation of MMP9 and soluble E-cadherin). 24hr p

  19. Slide 19: Human Tissue Model of Vitiligo – Reduction of Soluble E-cadherin

    VYN201: Human Tissue Model of Vitiligo – Reduction of Soluble E-cadherin 800 700 600 • Stimulated and vehicle-treated RHE (% untreated unstimulated CTL) 500 488 demonstrated a significant 422 upregulation of soluble E-cadherin, Soluble E-cadherin 359 relative to unstimulated control 400 328 • VYN201

  20. Slide 20: Human Tissue Model of Vitiligo – Effect on Melanocyte Retention

    VYN201: Human Tissue Model of Vitiligo – Effect on Melanocyte Retention 700 Relative melanin content in basal layers (% relative to the stimulated 498 600 367 • Stimulated and vehicle-treated RHE 500 demonstrated a significant loss in melanin content, relative to 400 290 unstimulated control control

  21. Slide 21: Human Tissue Model of Vitiligo - Histology

    VYN201: Human Tissue Model of Vitiligo - Histology Micrographic images of TRV immuno-stained induced RHE specimens demonstrating the preservation of melanocytes in the basal layer of samples treated with VYN201 1% Melanocyte migration Basal layer Retention of melanocytes at the basal layer Unstimula

  22. Slide 22: Human Tissue Model of Vitiligo – Gene regulation

    VYN201: Human Tissue Model of Vitiligo – Gene regulation Preliminary data suggest that VYN201 regulates genes relevant to Vitiligo including impacting WNT pathway which is believed to play a key role in melanocyte regeneration Transcriptome volcano plots of genes relevant to vitiligo (preliminary fi

  23. Slide 23: Phase 1a/b Study Design in Vitiligo

    VYN201: Phase 1a/b Study Design in Vitiligo Topline results anticipated in 1H 2023 Vitiligo Phase 1a/b design comprising of: Phase 1a Portion (N=30: 5 Cohorts with 6 patients each) A single ascending / multiple ascending dose cohort in healthy volunteer participants for up to 2 weeks of once- daily

  24. Slide 24: Vitiligo Represents an Exciting Opportunity for VYN201

    Vitiligo Represents an Exciting Opportunity for VYN201 First-in-human Phase 1a/b results anticipated in 1H 2023 Novel Mechanism of Action Significant Unmet Need with Encouraging Preclinical Data • Vitiligo is a disabling disease impacting • Novel MOA with high scientific rationale social, sexual and

  25. Slide 25: VYN202: BD2 selective BET inhibitor

    VYN202: BD2 selective BET inhibitor

  26. Slide 26: VYN202 Program Highlights & Molecular Profile

    VYN202 Program Highlights & Molecular Profile VYN202 is an oral BET inhibitor designed to selectively bind to BD2 and is being developed for major immuno-inflammatory diseases Potential Target Market1: Potency vs. BD2 • Immuno-inflammatory indications such as rheumatoid arthritis, systemic lupus ery

  27. Slide 27: FMX114 Tofacitinib and Fingolimod Topical Gel for Atopic Dermatitis

    FMX114 Tofacitinib and Fingolimod Topical Gel for Atopic Dermatitis 27

  28. Slide 28: FMX114: Atopic Dermatitis Market

    FMX114: Atopic Dermatitis Market Significant and rapidly growing Market Opportunity High prevalence impacting 10.7 to 13.0% of children1 and 7.3 to 10.6% of adults in the U.S.1 The U.S. represents ~80% of Global AD market Moderate-to- the global projected to grow severe AD market market2 from $6.4B

  29. Slide 29: FMX114: Two Validated Modes of Action

    FMX114: Two Validated Modes of Action Designed to address both the source & cause of inflammation in AD Tofacitinib (Janus kinase Inhibitor) Reduces Fingolimod (Sphingosine 1-phosphate receptor inflammation intracellularly by inhibiting cytokine release from modulator) Reduces inflammation by inhibi

  30. Slide 30: FMX114: Potential for a series of firsts in atopic dermatitis

    FMX114: Potential for a series of firsts in the treatment of atopic dermatitis FMX114 has the potential to be the: • 1st topical combination product for the treatment of atopic dermatitis • 1st topical product containing a sphingosine 1-phosphate receptor modulator (S1PRM) • S1PRM’s that are in deve

  31. Slide 31: FMX114: Targeting a Multi-factorial Solution for a Multi-factorial Disease

    FMX114: Targeting A Multi-factorial Solution for a Multi-factorial Disease Comparison to select topical products approved or in development for the treatment of AD: Aryl FMX114 JAK PDE4 hydrocarbon Gluco- Calcineurin Characteristic Target Inhibitors Inhibitors receptor Corticosteroids Inhibitors Pro

  32. Slide 32: FMX114 Phase 1b/2a Proof of Concept Study Design

    FMX114 Phase 1b/2a Proof of Concept Study Design Randomized, double-blinded, vehicle-controlled Phase 1b/2a trial with separate open-label active treatment phase evaluating the safety, pharmacokinetics & efficacy of FMX114 gel vs. vehicle gel in the treatment of mild-to-moderate atopic dermatitis FM

  33. Slide 33: FMX114 Phase 1b Safety and Pharmacokinetics

    FMX114 Phase 1b Safety and Pharmacokinetics Highlights • Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents • Mean Cmax of tofacitinib 50-fold and 1500-fold lower at Day 1 and 14 of s

  34. Slide 34: FMX114 Phase 1b Efficacy Data

    FMX114 Phase 1b Efficacy Data Highlights At week 2, FMX114 demonstrated a statistically significant reduction in both absolute and percent change in ADSI score compared to vehicle 0 Absolute and percent change relative to baseline in ADSI score at week 2: -10 Percent Reduction in ADSI Score • Mean A

  35. Slide 35: FMX114 Phase 2a Efficacy Data

    FMX114 Phase 2a Efficacy Data Highlights • Efficacy data for the Phase 2a trial was measured based on the absolute and percent change relative to baseline in the ADSI scoring assessment at week 4: • FMX114 was statistically superior to vehicle up to and including week 3; numerically superior at week

  36. Slide 36: FMX114 Phase 2a Subanalyses

    FMX114 Phase 2a Subanalyses Percent Reduction in ADSI Score by Baseline Score Baseline ADSI score of 6 through 91 Baseline ADSI score of 7 through 91 Baseline ADSI score of 8 through 91 (Mean ADSI = 6.6 active; 6.9 vehicle) (Mean ADSI = 7.6 active; 7.9 vehicle) (Mean ADSI = 8.7 active; 8.7 vehicle)

  37. Slide 37: FMX114 Phase 1b/2a Results Summary

    FMX114 Phase 1b/2a Results Summary  FMX114 drug effect and proof-of-concept established • On target PK and safety profile met • Statistically significant efficacy results at weeks 1, 2 and 3; Primary efficacy endpoint at week 4 not met but numerically superior • Continued effect demonstrated throug

  38. Slide 38: Phase 2b Study Design Applies Key Learnings from Phase 2a

    Phase 2b Study Design Applies Key Learnings from Phase 2a: Phase 2a Key Learnings & Rationale Phase 2b • 2-arm double-blind intra-lesional • Eliminate risk of patients using active • Conventional 4-arm double blind design design with patient acting as self- drug on lesions assigned to vehicle (pivot

  39. Slide 39: Potential Value-Creating Milestones To Kick-Off 2023

    Potential Value-Creating Milestones To Kick-Off 2023 Building a leading early-stage immuno-inflammatory pipeline VYN201 VYN201 2023: Selection of 2nd indication / FMX114 VYN201 1H 2023: Phase 1a/b TLR clinic ready Review Phase 1b/2a results Phase 1a/b FPI (vitiligo) (non-topical administration) Q4:2

  40. Slide 40: Appendix: VYN201 Preclinical data

    Appendix: VYN201 Preclinical data 40

  41. Slide 41: Th17 Inflammation Model

    VYN201: Th17 Inflammation Model

  42. Slide 42: Comparable Efficacy to Superpotent Steroid Clobetasol in Th17 Model

    VYN201: Comparable Efficacy to Superpotent Steroid Clobetasol in a TH17-Mediated Murine Inflammation Model; Potential for Greater Tolerability Dorsal depilated BALB-C mice were dosed topically for 14 days with 100mg topical IMI cream (Day 1-7: induction phase, Day 8- 14: treatment phase). N=4 animal

  43. Slide 43: Normal Skin Physiology in TH17 Model Suggests VYN201 Well Tolerated

    VYN201: Normal Skin Physiology in TH17-Mediated Murine Inflammation Model Suggests VYN201 Well Tolerated (Day 7) VYN201 Vehicle VYN201 0.1% Clobetasol Cream 0.05% • No appreciable improvement in • Substantial resolution of clinical signs • Substantial resolution of clinical signs clinical signs • Sk

  44. Slide 44: VYN201 Significantly Reduced Expression of Key Pro-Inflammatory Proteins

    VYN201 Significantly Reduced Expression of Several Key Pro-Inflammatory Proteins Relevant to Th17-mediated Autoimmune Diseases in Human Tissue1 >95% Inhibition seen with assays for IL-36γ & -99.5% LP-10 120 Percent inhibition (IL-17α) 100 Interleukin 36-gamma 80 60 IL36γ is implicated in upregulatin

  45. Slide 45: Fibrotic Tissue & IPF Models

    VYN201: Fibrotic Tissue & IPF Models

  46. Slide 46: Demonstrated Anti-Fibrotic Activity in Murine Skin Healing Model

    VYN201: Demonstrated Anti-Fibrotic Activity without Delay in Healing Time in Murine Skin Healing Model Female hairless mice (n=4/group) had two identical 10mm incisions made either side of the flank. Animals were topically dosed 1X daily with 100mg VYN201 vehicle, VYN201 1% or a Hydroalcoholic gel*

  47. Slide 47: Little Evidence of Residual Swelling and Macular Wound Appearance

    VYN201: Little Evidence of Residual Swelling and Macular Wound Appearance in Murine Skin Healing Model VYN201 Vehicle VYN201 1% Hydroalcoholic gel • Still evidence of minor swelling • Little evidence of residual swelling • Moderate swelling clearly evident at around incision sites • Wound appears mo

  48. Slide 48: Bleomycin-induced mouse model of IPF - Histology

    VYN201: Bleomycin-induced mouse model of IPF - Histology Histology images indicate positive impact of VYN201 0.06mg/ml on fibrosis in lungs. Additional preclinical exploration planned Healthy sham control Bleomycin control Bleomycin + 0.06mg/ml VYN201 A: Normal lung parenchyma with open B: Conductin

  49. Slide 49: Arthritis

    VYN201: Arthritis eV YNE’

  50. Slide 50: CAIA Mouse Model of Arthritis – Paw Thickness

    VYN201: CAIA Mouse Model of Arthritis – Paw Thickness Marked inhibition of paw thickening/swelling Inflammatory arthritis was induced in BALB/C mice using a mixture of four arthritogenic MAbs by IV injection at Day 0 and was further challenged with an LPS IV injection at Day 4 (N=7/treatment group).

  51. Slide 51: CAIA Mouse Model of Arthritis – Arthritis Score

    VYN201: CAIA Mouse Model of Arthritis – Arthritis Score Demonstrated dose dependent reduction in disease severity 3.50 VYN201 VYN201 VYN201 Vehicle IA 10mg/kg IA 1mg/kg IA Clear dose-response demonstrated between VYN201 VYN201 Dexamethasone 3.00 0.1mg/kg IA 0.01 mg/kg IA 1mg/kg IP VYN201-treated gro

  52. Slide 52: CAIA Mouse Model of Arthritis – Systemic Impact

    VYN201: CAIA Mouse Model of Arthritis – Systemic Impact Demonstrated localized dose-dependent effect 2.00 Paw Thickness VYN201 VYN201 VYN201 VYN201 Vehicle IA 10mg/kg IA 1mg/kg IA 0.1mg/kg IA 1.50 VYN201 Dexamethasone Dexamethasone 0.01 mg/kg IA 1mg/kg IP 1mg/kg IA Δ untreated - treated leg Paw thic

  53. Slide 53: CAIA Mouse Model of Arthritis – Histopathology

    VYN201: CAIA Mouse Model of Arthritis – Histopathology Joint histopathology confirmed arthritis clinical scoring & local effect Inflammation marked with asterisk; damage to bone marked with a blue arrow; inflammatory cells and cellular debris in the joint space marked with red arrow; damage to carti

  54. Slide 54: NASDAQ: VYNE

    rd a THERAPEUTICS NASDAQ: VYNE

VYNE Therapeutics — Investor Presentation (January 2023) on 6ix